Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices.
Atezolizumab plus bevacizumab
Hepatocellular carcinoma
Portal hypertension
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
18
03
2023
accepted:
11
07
2023
pubmed:
2
8
2023
medline:
2
8
2023
entrez:
1
8
2023
Statut:
ppublish
Résumé
Bevacizumab inhibits vascular endothelial growth factor-A (VEGF-A), though is known to increase bleeding risk as an adverse event (AE). This study examined whether atezolizumab/bevacizumab (Atez/Bev) for unresectable hepatocellular carcinoma (uHCC) can be used for patients with esophageal-gastric varices (EGV). From October 2020 to December 2022, 506 uHCC patients (median 74 years) underwent an upper gastrointestinal endoscopy examination were enrolled, after exclusion of those with portal vein tumor thrombus (PVTT). Patients with EGV (≧ F1) were defined as EGV positive, and the cohort was divided into non-EGV (n = 355) and EGV (n = 151). Before introducing Atez/Bev, endoscopic treatment was performed, when necessary. Prognosis was evaluated, retrospectively. The EGV group had significantly worse hepatic function, lower platelet count, elevated alpha-fetoprotein, and lower rate of extrahepatic metastasis, and lower rate of first-line use (each P < 0.05) than the other. However, progression-free survival (PFS) was also not a significantly difference between the EGV and non-EGV groups in analyses with (PFS rate at 6/12/18 months: 60%/38%/30% vs. 65%/46%/34%, P = 0.29) or without inverse probability weighting adjustment [median: 10.6 months (95% CI 8.3-14.0) vs. 10.5 months (95% CI 7.8-13.7), P = 0.79]. As for AEs, diarrhea was more frequent in the EGV group (≧ G3: 2.0% vs. 0.3%, P = 0.036), while no significant difference was noted for EGV hemorrhage (≧ G3: 1.3% vs. 0.6%, P = 0.345). Of 28 patients who underwent endoscopic treatments before introducing Atez/Bev, none showed EGV-associated hemorrhage. Atez/Bev might be an effective therapeutic option in patients with EGV, when appropriate endoscopic treatment for EGV is performed.
Sections du résumé
BACKGROUND
BACKGROUND
Bevacizumab inhibits vascular endothelial growth factor-A (VEGF-A), though is known to increase bleeding risk as an adverse event (AE). This study examined whether atezolizumab/bevacizumab (Atez/Bev) for unresectable hepatocellular carcinoma (uHCC) can be used for patients with esophageal-gastric varices (EGV).
METHODS
METHODS
From October 2020 to December 2022, 506 uHCC patients (median 74 years) underwent an upper gastrointestinal endoscopy examination were enrolled, after exclusion of those with portal vein tumor thrombus (PVTT). Patients with EGV (≧ F1) were defined as EGV positive, and the cohort was divided into non-EGV (n = 355) and EGV (n = 151). Before introducing Atez/Bev, endoscopic treatment was performed, when necessary. Prognosis was evaluated, retrospectively.
RESULTS
RESULTS
The EGV group had significantly worse hepatic function, lower platelet count, elevated alpha-fetoprotein, and lower rate of extrahepatic metastasis, and lower rate of first-line use (each P < 0.05) than the other. However, progression-free survival (PFS) was also not a significantly difference between the EGV and non-EGV groups in analyses with (PFS rate at 6/12/18 months: 60%/38%/30% vs. 65%/46%/34%, P = 0.29) or without inverse probability weighting adjustment [median: 10.6 months (95% CI 8.3-14.0) vs. 10.5 months (95% CI 7.8-13.7), P = 0.79]. As for AEs, diarrhea was more frequent in the EGV group (≧ G3: 2.0% vs. 0.3%, P = 0.036), while no significant difference was noted for EGV hemorrhage (≧ G3: 1.3% vs. 0.6%, P = 0.345). Of 28 patients who underwent endoscopic treatments before introducing Atez/Bev, none showed EGV-associated hemorrhage.
CONCLUSIONS
CONCLUSIONS
Atez/Bev might be an effective therapeutic option in patients with EGV, when appropriate endoscopic treatment for EGV is performed.
Identifiants
pubmed: 37528255
doi: 10.1007/s00535-023-02026-2
pii: 10.1007/s00535-023-02026-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1134-1143Informations de copyright
© 2023. Japanese Society of Gastroenterology.
Références
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
pubmed: 30207593
doi: 10.3322/caac.21492
Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(335–49): e15.
Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet. 2022;400:1345–62.
pubmed: 36084663
doi: 10.1016/S0140-6736(22)01200-4
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.
pubmed: 18650514
doi: 10.1056/NEJMoa0708857
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.
pubmed: 29433850
doi: 10.1016/S0140-6736(18)30207-1
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.
pubmed: 27932229
doi: 10.1016/S0140-6736(16)32453-9
Zhu AX, Finn RS, Galle PR, et al. Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alpha-fetoprotein. Lancet Oncol. 2019;20: e191.
pubmed: 30942178
doi: 10.1016/S1470-2045(19)30165-2
Kudo M, Tsuchiya K, Kato N, et al. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol. 2021;56:181–90.
pubmed: 33392749
pmcid: 7862203
doi: 10.1007/s00535-020-01753-0
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.
pubmed: 32402160
doi: 10.1056/NEJMoa1915745
Chuma M, Uojima H, Hattori N, et al. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: a multicenter analysis. Hepatol Res. 2022;52:269–80.
pubmed: 34761470
doi: 10.1111/hepr.13732
Hiraoka A, Kumada T, Tada T, et al. Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - multicenter analysis. Hepatol Res. 2022;52:308–16.
pubmed: 34799975
doi: 10.1111/hepr.13734
Maesaka K, Sakamori R, Yamada R, et al. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. Hepatol Res. 2022;52:630–40.
pubmed: 35417606
doi: 10.1111/hepr.13771
Tajiri T, Yoshida H, Obara K, et al. General rules for recording endoscopic findings of esophagogastric varices (2nd edition). Dig Endosc. 2010;22:1–9.
pubmed: 20078657
doi: 10.1111/j.1443-1661.2009.00929.x
The Japan Society for Portal Hypertension. Clinical manual of portal hypertension: diagnosis and treatment of esophageal and gastric varices. Tokyo: Nankodo; 2015. p. 50–4.
Krige JE, Shaw JM, Bornman PC. The evolving role of endoscopic treatment for bleeding esophageal varices. World J Surg. 2005;29:966–73.
pubmed: 15981047
doi: 10.1007/s00268-005-0138-2
Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J Gastroenterol. 2021;56:593–619.
pubmed: 34231046
pmcid: 8280040
doi: 10.1007/s00535-021-01788-x
European Association for the Study of the Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57:399–420.
doi: 10.1016/j.jhep.2012.04.004
Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47(Suppl):S2-6.
pubmed: 23632345
pmcid: 3683119
doi: 10.1097/MCG.0b013e3182872f29
Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.
pubmed: 4541913
doi: 10.1002/bjs.1800600817
Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–8.
pubmed: 25512453
doi: 10.1200/JCO.2014.57.9151
Hiraoka A, Kumada T, Michitaka K, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1031–6.
pubmed: 26647219
doi: 10.1111/jgh.13250
Hiraoka A, Michitaka K, Kumada T, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer. 2017;6:325–36.
pubmed: 29234636
pmcid: 5704689
doi: 10.1159/000479984
Bruix J, Sherman M. Practice Guidelines Committee AAftSoLD management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.
pubmed: 16250051
doi: 10.1002/hep.20933
Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010;256:806–16.
pubmed: 20720069
doi: 10.1148/radiol.10091334
Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology. 2011;261:834–44.
pubmed: 21998047
doi: 10.1148/radiol.11101840
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93.
pubmed: 34801630
doi: 10.1016/j.jhep.2021.11.018
Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50 . Accessed 7 Mar 2023.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
pubmed: 19097774
doi: 10.1016/j.ejca.2008.10.026
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
pubmed: 20175033
doi: 10.1055/s-0030-1247132
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
pubmed: 23208313
doi: 10.1038/bmt.2012.244
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
doi: 10.1016/j.jhep.2018.03.019
Li X, Feng GS, Zheng CS, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10:2878–82.
pubmed: 15334691
pmcid: 4572123
doi: 10.3748/wjg.v10.i19.2878
Mukozu T, Nagai H, Matsui D, et al. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma. Anticancer Res. 2013;33:1013–21.
pubmed: 23482775
Fernandez M. Molecular pathophysiology of portal hypertension. Hepatology. 2015;61:1406–15.
pubmed: 25092403
doi: 10.1002/hep.27343
Nakayama H, Masuda H, Miyake H, et al. Endoscopic prediction of hepatocellular carcinoma by evaluation of bleeding esophageal varices. Digestion. 2004;70:233–9.
pubmed: 15627772
doi: 10.1159/000082895
Ripoll C, Groszmann RJ, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009;50:923–8.
pubmed: 19303163
pmcid: 3721146
doi: 10.1016/j.jhep.2009.01.014
Ishikawa T, Egusa M, Fujioka T, et al. A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension. J Gastroenterol. 2023;58:246–56.
pubmed: 36583759
doi: 10.1007/s00535-022-01947-8
Tanaka T, Hiraoka A, Tada T, et al. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. Hepatol Res. 2022;52:773–83.
pubmed: 35633504
doi: 10.1111/hepr.13797
Tateishi R, Matsumura T, Okanoue T, et al. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol. 2021;56:261–73.
pubmed: 33427937
pmcid: 7932951
doi: 10.1007/s00535-020-01754-z
Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatol Res. 2021;51:1013–25.
pubmed: 34533266
doi: 10.1111/hepr.13688
Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol. 2004;18:353–72.
pubmed: 15123075
doi: 10.1016/j.bpg.2003.10.005
Simbrunner B, Mandorfer M, Trauner M, et al. Gut-liver axis signaling in portal hypertension. World J Gastroenterol. 2019;25:5897–917.
pubmed: 31660028
pmcid: 6815800
doi: 10.3748/wjg.v25.i39.5897
Su GL, Altayar O, O’Shea R, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162:920–34.
pubmed: 35210014
doi: 10.1053/j.gastro.2021.12.276
Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:EVIDoa2100070.
doi: 10.1056/EVIDoa2100070
Llovet JM, Pinyol R, Kelley RK, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3:386–401.
pubmed: 35484418
pmcid: 9060366
doi: 10.1038/s43018-022-00357-2
Bejjani AC, Finn RS. Hepatocellular carcinoma: pick the winner-tyrosine kinase inhibitor versus immuno-oncology agent-based combinations. J Clin Oncol. 2022;40:2763–73.
pubmed: 35649192
doi: 10.1200/JCO.21.02605
Iavarone M, Primignani M, Vavassori S, et al. Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. United Eur Gastroenterol J. 2016;4:363–70.
doi: 10.1177/2050640615615041
Breder VV, Vogel A, Merle A, et al. IMbrave150: exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study. J Clin Oncol 2021;39(15_suppl):4073.
doi: 10.1200/JCO.2021.39.15_suppl.4073